MX9602683A
(en )
1997-06-28
6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
EP0828481A4
(en )
1999-06-09
Oral dosage composition for intestinal delivery and method of use of the same
TWI235068B
(en )
2005-07-01
Sustained-release pharmaceutical composition
CA2259148A1
(en )
1997-12-31
Solid oral dosage forms of valsartan
IL120382A
(en )
2003-06-24
Extended release formulation of venlafaxine hydrochloride
AU1227899A
(en )
1999-05-17
Osmotic medicament releasing system
YU33099A
(en )
2002-06-19
Pharmaceutical composition
MY129356A
(en )
2007-03-30
Electrospun pharmaceutical compositions
MY114889A
(en )
2003-02-28
1-phenyl-3-dimethylamino-propane derivatives having pharmacological activity
MX9605023A
(en )
1997-06-28
Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
CA2427815A1
(en )
2002-05-10
Controlled release hydrocodone formulations
PT893992E
(en )
2004-06-30
FORMS OF FAST DISINTEGRATION ORAL DOSAGE
AU5651696A
(en )
1996-10-30
Substituted 1-phenyl-3-pyrazolecarboxamides active on nurotensin receptors, their preparation and pharmaceutical compositions containing them
NZ298769A
(en )
2000-09-29
use of progesterone-antagonistic and anti-estrogen compounds in a single dose for female contraception
CA2294783A1
(en )
1999-01-14
Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
CA2622805A1
(en )
2000-07-06
Compressed tablets comprising valsartan
NZ504460A
(en )
2003-01-31
Sustained release formulations containing venlafaxine
CA2325739A1
(en )
1999-09-30
Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
HK1039273A1
(en )
2002-04-19
Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
HRP20010684B1
(en )
2011-01-31
Directly compressible matrix for controlled release of single daily doses of clarithromycin
IL150528A0
(en )
2003-02-12
Ibuprofen containing active agent preparation
MX9603606A
(en )
1997-03-29
N-methyl-n-[(1s)-1-phenyl-2-((3s)-3-hydroxypirrolidin-1-yl)ethyl]-2,2-di phenyl-acetamide.
WO2002015933A3
(en )
2003-08-14
Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
MX9708394A
(en )
1998-02-28
Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation.
ZA966047B
(en )
1997-02-04
Therapeutic agents.